Live Breaking News & Updates on Institutional Trading Of Atea Pharmaceuticals

Stay updated with breaking news from Institutional trading of atea pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Analysts Offer Predictions for Atea Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […] ....

Dwayne Foster , Andrea Corcoran , Leerink Partnrs , Atea Pharmaceuticals Trading , Blackrock Inc , News Ratings For Atea Pharmaceuticals Daily , Insider Activity At Atea Pharmaceuticals , Advisor Group Holdings Inc , Metlife Investment Management , Jpmorgan Chase Co , Atea Pharmaceuticals , Institutional Trading Of Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Securities Exchange Commission , Envestnet Asset Management Inc , Free Report , Atea Pharmaceutical , Get Free Report , Exchange Commission , Asset Management , Group Holdings , Life Investment Management , Atea Pharmaceuticals Daily , Nasdaq Avir , Earnings Estimates ,

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 8.5% in September

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 1,920,000 shares, an increase of 8.5% from the August 31st total of 1,770,000 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average daily trading […] ....

Atea Pharmaceuticals Price Performance , Advisor Group Holdings Inc , Envestnet Asset Management Inc , Atea Pharmaceuticals Company Profile , Jpmorgan Chase Co , Institutional Trading Of Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Atea Pharmaceuticals , Lazard Asset Management , Osaic Holdings Inc , Royal Bank , News Ratings For Atea Pharmaceuticals Daily , Get Free Report , Group Holdings , Asset Management , Osaic Holdings , Atea Pharmaceuticals Daily , Nasdaq Avir ,

JPMorgan Chase & Co. Downgrades Atea Pharmaceuticals (NASDAQ:AVIR) to Underweight

JPMorgan Chase & Co. Downgrades Atea Pharmaceuticals (NASDAQ:AVIR) to Underweight
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Institutional Trading Of Atea Pharmaceuticals , Capital Management , Atea Pharmaceuticals Company Profile , Blackrock Inc , Vanguard Group Inc , Atea Pharmaceuticals Inc , Atea Pharmaceuticals , Hermes Inc , Jpmorgan Chase Co , Atea Pharmaceuticals Price Performance , News Ratings For Atea Pharmaceuticals Daily , Free Report , State Street Corp , Street Corp , Get Free Report , Atea Pharmaceuticals Daily ,

Q1 2023 EPS Estimates for Atea Pharmaceuticals, Inc. Increased by SVB Leerink (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […] ....

Morgan Stanley , Geode Capital Management , Atea Pharmaceuticals Trading , Blackrock Inc , Vanguard Group Inc , News Ratings For Atea Pharmaceuticals Daily , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Hermes Inc , Institutional Trading Of Atea Pharmaceuticals , Get Rating , Atea Pharmaceutical , Street Corp , Capital Management , Atea Pharmaceuticals Daily , Nasdaq Avir , Earnings Estimates , Svb Leerink Llc ,

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Down 12.9% in September

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 2,300,000 shares, a decrease of 12.9% from the August 31st total of 2,640,000 shares. Based on an average trading volume of 471,500 shares, the short-interest ratio is […] ....

Morgan Stanley , Atea Pharmaceuticals Trading , Goldman Sachs Group Inc , News Ratings For Atea Pharmaceuticals Daily , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Hermes Inc , Group Plc , Institutional Trading Of Atea Pharmaceuticals , Get Rating , General Group Plc , Point Capital Management , Sachs Group , Wexford Capital , Atea Pharmaceuticals Daily , Nasdaq Avir ,